<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048684</url>
  </required_header>
  <id_info>
    <org_study_id>FG2010-003</org_study_id>
    <nct_id>NCT01048684</nct_id>
  </id_info>
  <brief_title>Comparison of Two Doses of Mannitol on Brain Relaxation During Supratentorial Craniotomy</brief_title>
  <official_title>Comparison of Two Doses of Mannitol on Brain Relaxation During Supratentorial Craniotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuroanesthesia for supratentorial surgery involves a thorough understanding of the&#xD;
      physiopathology of intracranial pressure, cerebral homeostasis and regulation of cerebral&#xD;
      perfusion pressure as well as the effects of anesthesia and surgery on these elements.&#xD;
&#xD;
      The main objective of anesthesia during neurosurgery is to preserve the integrity of the&#xD;
      brain by maintaining cerebral homeostasis, and assuring cerebral protection using&#xD;
      normovolemia, normotension, normoglycemia, moderate hyperoxia and hypocapnia and&#xD;
      hyperosmolality with the administration of mannitol.&#xD;
&#xD;
      During surgery, the use of surgical retractors must be limited to avoid possible ischemia of&#xD;
      the brain tissue. Surgical retractors can be replaced by chemical retractors. The concept of&#xD;
      chemical retraction involves a reduction of cerebral blood flow, maintaining cerebral&#xD;
      perfusion pressure, moderate hyperventilation, drainage of cerebrospinal fluid and&#xD;
      osmotherapy.&#xD;
&#xD;
      Mannitol, an osmotic agent, has been widely used to reduce the volume of the brain, the&#xD;
      intracranial pressure and to facilitate the surgical approach in reducing the risk of&#xD;
      cortical lesions during the opening of the skull.&#xD;
&#xD;
      Mannitol 20% is usually given intravenously in bolus doses of 0.5-1g/kg over 30 minutes.&#xD;
      However, over the last few years, the concept of a dose-response relationship has emerged.&#xD;
      Some recent studies tend to demonstrate that higher doses of mannitol could reduce&#xD;
      intracranial pressure significantly without any important side effects.&#xD;
&#xD;
      The main objective of the present study is to compare two doses of mannitol (0.7 and 1.4&#xD;
      g/kg) on brain relaxation during supratentorial craniotomies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      80 patients will be divided in two equal groups (Group 1: to receive 20% mannitol 0.7 g/kg or&#xD;
      Group 2: 1.4 g/kg).&#xD;
&#xD;
      The anesthetic technique and monitoring will be standardized. The administration of mannitol&#xD;
      will start following the induction of general anesthesia. The infusion will be given&#xD;
      intravenously over 30 minutes.&#xD;
&#xD;
      Brain relaxation will be assessed by a senior surgeon at the opening of the dura mater on a&#xD;
      scale from 1 to 4 (1= perfectly relaxed, 2= satisfactorily relaxed, 3= firm brain, 4=bulging&#xD;
      brain)&#xD;
&#xD;
      If needed, in case of significant cerebral edema, a rescue dose of 20% mannitol 0.25 g/kg&#xD;
      will be administered.&#xD;
&#xD;
      Hemodynamic variables (MAP, heart rate), temperature, urine output, perioperative fluid&#xD;
      balance, blood loss and laboratory values (blood gases, electrolytes, osmolality, hematocrit,&#xD;
      glycemia, lactates) will be collected immediately prior to the infusion of mannitol and at&#xD;
      30, 60, 180 minutes following the administration of mannitol.&#xD;
&#xD;
      The type of cerebral lesion, its location and size (in 3 dimensions) will be noted. The&#xD;
      presence of a median-line shift will also be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain relaxation at the opening of the dura mater assessed by a senior surgeon on a scale from 1 to 4 (1= perfectly relaxed, 2= satisfactorily relaxed, 3= firm brain, 4=bulging brain)</measure>
    <time_frame>At the opening of the dura mater</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic variables: MAP, heart rate</measure>
    <time_frame>Immediately prior to the infusion of mannitol and at 30, 60, 180 minutes after the administration of mannitol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature</measure>
    <time_frame>Immediately prior to the infusion of mannitol and at 30, 60, 180 minutes after the administration of mannitol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine output</measure>
    <time_frame>Immediately prior to the infusion of mannitol and at 30, 60, 180 minutes after the administration of mannitol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative fluid balance and blood loss</measure>
    <time_frame>Immediately prior to the infusion of mannitol and at 30, 60, 180 minutes after the administration of mannitol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory data: blood gases, electrolytes, osmolality, hematocrit, glycemia, lactates</measure>
    <time_frame>Immediately prior to the infusion of mannitol and at 30, 60, 180 minutes after the administration of mannitol</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Brain Tumor</condition>
  <condition>Intracranial Pressure</condition>
  <arm_group>
    <arm_group_label>20% Mannitol 0.7 g/kg (low-dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subjects will be randomized to receive an infusion of 20% mannitol 0.7g/kg over 30 minutes after induction of general anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20% Mannitol 1.4 g/kg (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will be randomized to receive an infusion of 20% mannitol 1.4 g/kg over 30 minutes after induction of general anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>Variation of mannitol dose</description>
    <arm_group_label>20% Mannitol 0.7 g/kg (low-dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>Variation of mannitol dose</description>
    <arm_group_label>20% Mannitol 1.4 g/kg (high dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 or older&#xD;
&#xD;
          -  Patients who are to undergo an elective supratentorial craniotomy&#xD;
&#xD;
          -  Physical status ASA I to IV inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe congestive heart failure&#xD;
&#xD;
          -  Severe chronic renal failure&#xD;
&#xD;
          -  Recent use (less than 24 hours before surgery)of mannitol or other hypertonic solution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Girard, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal-Hôpital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>François Girard MD FRCPC</name_title>
    <organization>Centre de recherche du CHUM (CRCHUM)</organization>
  </responsible_party>
  <keyword>Brain tumor</keyword>
  <keyword>Intracranial pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

